ALB — Albemarle Corporation

As of 2026-09-13, the stock was at $117.52, down 6.94% in one week, 8.43% in one month, and 31.04% in three months, trading 24.98% below its 200-day SMA. Q2 2026 revenue rose 31% YoY to $1.74B and net income hit $480M, but investors are focused on lithium spot prices around $18,000-$20,000/t, potential Chinese supply restarts, and late-August analyst target cuts from JPMorgan ($160 to $140), RBC ($166 to $157), and Scotiabank ($200 to $190).

The 3-year quarterly trend is a classic cyclical trough-and-inflection, not a structural decline. Revenue collapsed from $2.36B in Q4 2023 to a trough of $1.08B in Q1 2025, then recovered gradually to $1.43B in Q1 2026 and accelerated sharply to $1.74B in Q2 2026 (+31% YoY, +22% QoQ). Margins tell the same story: Q2 2026 gross margin was 33.9% and operating margin 26.0%, versus Q2 2025 operating margin of 4.0%, Q3 2025 operating margin of -2.3%, and Q4 2025 operating margin of 3.4%. Net income swung from -$160.7M in Q3 2025 and -$414.2M in Q4 2025 to +$319.1M in Q1 2026 and +$480.0M in Q2 2026. The 2024-2025 losses were heavily distorted by impairments and lithium-price trough economics, so trailing TTM metrics understate the current run-rate.

As of 2026-09-13, ALB looked cheap on forward earnings and fair-to-cheap on assets/sales, but expensive on distorted trailing numbers. The TTM P/E of 244.8x is meaningless because TTM EPS is only $1.90 after the lithium trough. Using next-FY consensus EPS of $11.478, the forward P/E is about 10.2x, versus analyst target-implied multiples of roughly 16x on the recent average target of $183.40 and 17.6x on the consensus target of $202.63. P/B is 1.35x, P/S is 2.35x versus a 5-year average P/S of 3.70x, and EV/EBITDA is 13.3x on trailing numbers. The forward multiple is undemanding if lithium stabilizes, but the discount reflects real commodity-cycle risk.

The stock is pricing in a much weaker lithium cycle than Q2 2026 results imply. Q2 2026 annualized EPS of roughly $12.88 ($3.22 diluted x 4) would put the stock at about 9.1x, while next-FY consensus EPS of $11.478 puts it at 10.2x. If forward estimates hold, the market is underpricing the turnaround. If lithium spot prices fall below $18,000/t and estimates get cut, the stock is correctly discounting a rollover. The key is Q3 2026 realized pricing and whether the Q2 margin/FCF inflection is sustainable.

As of 2026-09-13, RSI was 34.95, close to oversold but not below 30. The stock was 11.6% below its 20-day SMA, 7.6% below its 50-day SMA, and 24.98% below its 200-day SMA, with negative 1-week, 1-month, 3-month, and 6-month returns. This is a clear downtrend with short-term oversold conditions. Entry-timing implication: an oversold bounce is possible, but the trend has not reversed; waiting for a reclaim of the 20-day SMA or a higher low would reduce catching-a-falling-knife risk.

• Lithium spot prices remain volatile around $18,000-$20,000/t, with oversupply fears triggered by reports of potential restarts of Chinese capacity such as CATL's Jianxiawo mine.
• Secular EV adoption and utility-scale energy storage demand provide long-term tailwinds, but near-term EV demand growth has moderated in key markets.
• Interest rates and cost of capital affect commodity producers and long-duration electrification themes; lower rates would help sentiment, higher rates would pressure multiples.
• Regulatory and environmental approvals in China, Chile, and other mining jurisdictions can shift global lithium supply balances and project timelines.
• Sector rotation within Basic Materials can amplify moves in specialty chemicals, especially when investors favor defensive or non-commodity sectors.

• Q3 2026 earnings in early November 2026: watch Energy Storage realized pricing, volume trends, and full-year FCF guidance.
• Lithium supply-side news, especially Chinese environmental/land-use approvals and any restart of idled capacity.
• CEO transition: Ragnar Udd becomes CEO on February 1, 2027, succeeding Kent Masters; strategic or operational shifts could follow.
• Further progress on the $100-$150M cost-and-productivity improvement target and Specialties EBITDA guidance of $275-$325M.
• Potential stabilization or recovery in lithium spot prices, which would likely drive estimate revisions and multiple expansion.

• Lithium oversupply and price declines could force downgrades to forward EPS estimates, making the current 10.2x forward P/E look less cheap.
• The Q2 2026 margin and FCF inflection may prove temporary if spot prices roll over or if customer destocking resumes.
• CEO transition risk: leadership change in early 2027 introduces execution uncertainty during a cyclical recovery.
• Regulatory or environmental setbacks at key lithium assets could disrupt volumes or raise costs.
• Commodity cyclicality and high beta (1.334) mean the stock can remain technically weak even as fundamentals improve.

Albemarle is a high-risk, cyclical recovery play with an undemanding forward valuation. Q2 2026 showed a sharp revenue, margin, and FCF inflection, the balance sheet is strong with debt-to-equity of 0.193 and $1.63B cash, and next-FY EPS estimates put the stock at just over 10x. The bear case is credible: lithium spot prices are well below prior peaks and oversupply headlines can keep pressuring the shares. For a patient, risk-tolerant investor, the risk/reward is attractive, but this is not a clean all-clear; scaling in and watching Q3 pricing is prudent.

Applied a 14.4x multiple to next-FY consensus EPS of $11.478, yielding $165.28. This multiple is below the recent analyst-target-implied ~16x and the consensus-target-implied ~17.6x, but above the current ~10.2x forward P/E to reflect the Q2 2026 margin/FCF inflection, low leverage, and cyclical lithium risk.